Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study.

Blood (2025) 146 (Supplement 1): 669.

https://doi.org/10.1182/blood-2025-669

Published: 2025

Journal Articles

Transformed FL shows improved survival after CAR T-cell therapy compared to de novo LBCL, but early transformation (<12 months) defines a poor-risk subgroup: Results from a nationwide cohort

Blood (2025) 146 (Supplement 1): 959.

https://doi.org/10.1182/blood-2025-959

Published: 2025

Journal Articles

Higher helios⁺ treg levels pre- and post-CAR T infusion are associated with inferior outcomes in patients with LBCL

Hilde Van Der Galien, Nienke Smit, Marije Nijk, Marieke Tienstra, Thies Moolenaar, Janneke De Boer, Kylie Keijzer, Jaap Van Doesum, Anne Niezink, Gerwin A. Huls, Kees Meijer, Tom Van Meerten

Blood (2025) 146 (Supplement 1): 1779.

https://doi.org/10.1182/blood-2025-1779

Published: 2025

Journal Articles

High risk of bleeding following CAR T-cell therapy: Insights from the dutch “Follow that CAR!” registry

Amica Ko, Pim Mutsaers, Lukas Van Kleij, Frank Leebeek, Amaria Vledder, Elise Pennings, Anne Spanjaart, Janneke De Boer, Astrid Demandt, Jaap Van Doesum, Suzanne Van Dorp, Margot Jak, Maria Kuipers, Tom Van Meerten, Marjolein Van Der Poel, Joost Vermaat, Marie José Kersten, Mandy Lauw

Blood (2025) 146 (Supplement 1): 315.

https://doi.org/10.1182/blood-2025-315

Published: 2025

Journal Articles

Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

Livio Pagano, Jon Salmanton-García, Francesco Marchesi, Ola Blennow, Maria Gomes da Silva, Andreas Glenthøj, Jaap van Doesum, Yavuz M. Bilgin, Alberto López-García, Federico Itri, Raquel Nunes Rodrigues, Barbora Weinbergerová, Francesca Farina, Giulia Dragonetti, Caroline Berg Venemyr, Jens van Praet, Ozren Jaksic, Toni Valković, Iker Falces-Romero, Sonia Martín-Pérez, Moraima Jiménez, Julio Dávila-Valls, Martin Schönlein, Emanuele Ammatuna, Stef Meers, Mario Delia, Zlate Stojanoski, Anna Nordlander, Tobias Lahmer, László Imre Pinczés, Caterina Buquicchio, Klára Piukovics, Irati Ormazabal-Vélez, Nicola Fracchiolla, Michail Samarkos, Gustavo-Adolfo Méndez, José-Ángel Hernández-Rivas, Ildefonso Espigado, Martin Cernan, Verena Petzer, Sylvain Lamure, Roberta di Blasi, Joyce Marques de Almedia, Michelina Dargenio, Monika M. Biernat, Mariarita Sciumè, Cristina de Ramón, Nick de Jonge, Josip Batinić, Avinash Aujayeb, Monia Marchetti, Guillemette Fouquet, Noemí Fernández, Giovanni Zambrotta, Maria Vittoria Sacchi, Anna Guidetti, Fatih Demirkan, Lucia Prezioso, Zdeněk Ráčil, Marcio Nucci, Miloš Mladenović, Raphaël Liévin, Michaela Hanáková, Stefanie Gräfe, Uluhan Sili, Marina Machado, Chiara Cattaneo, Tatjana Adžić-Vukičević, Luisa Verga, Jorge Labrador, Laman Rahimli, Matteo Bonanni, Francesco Passamonti, Antonio Pagliuca, Paolo Corradini, Martin Hoenigl, Philipp Koehler, Alessandro Busca, Oliver A. Cornely

Blood (2022) 140 (26): 2773–2787.

https://doi.org/10.1182/blood.2022017257

Published: 2022

Includes: Supplemental data

Journal Articles

Sickle Cell Disease Patients Mount Adequate Humoral but Reduced Cellular Responses to COVID-19 Vaccination

Blood (2022) 140 (Supplement 1): 1957–1959.

https://doi.org/10.1182/blood-2022-169164

Published: 2022

Journal Articles

Discordant Cellular and Humoral Responses to a 3-Dose COVID-19 mRNA Vaccination Schedule in Patients with Hematologic Malignancies

Blood (2022) 140 (Supplement 1): 8347–8349.

https://doi.org/10.1182/blood-2022-168991

Published: 2022

Journal Articles

COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA

Blood (2022) 139 (10): 1588–1592.

https://doi.org/10.1182/blood.2021014124

Published: 2022

Includes: Supplemental data

Journal Articles

Radiotherapy Is an Excellent Bridging Strategy in Large B-Cell Lymphoma Patients Selected for CAR T-Cell Therapy

Anne Niezink, Jaap van Doesum, Max Beijert, Marcel Nijland, Hans Langendijk, Dianne Busz, Anne P.G. Crijns, Gerwin A. Huls, Tom Van Meerten

Blood (2021) 138 (Supplement 1): 2510.

https://doi.org/10.1182/blood-2021-151404

Published: 2021

Journal Articles

For Better or for Worse: COVID-19 Vaccination during or Early after (Immuno-) Chemotherapy or Hematopoietic Progenitor Cell Transplantation

Sabine Haggenburg, Birgit I. Lissenberg-Witte, Robert S. Van Binnendijk, Gerco Den Hartog, Bhoekhan S. Michel, Nienke J.E. Haverkate, Dennis M. De Rooij, Annoek E.C. Broers, Pim G.N.J. Mutsaers, Tom Van Meerten, Jaap van Doesum, Arnon P. Kater, Sonja Zweegman, Marit J. Van Gils, Bram Goorhuis, Caroline E. Rutten, Mette D. Hazenberg, Inger S. Nijhof

Blood (2021) 138 (Supplement 1): 754.

https://doi.org/10.1182/blood-2021-150379

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study.

Transformed FL shows improved survival after CAR T-cell therapy compared to de novo LBCL, but early transformation (<12 months) defines a poor-risk subgroup: Results from a nationwide cohort

Higher helios⁺ treg levels pre- and post-CAR T infusion are associated with inferior outcomes in patients with LBCL

High risk of bleeding following CAR T-cell therapy: Insights from the dutch “Follow that CAR!” registry

Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

Sickle Cell Disease Patients Mount Adequate Humoral but Reduced Cellular Responses to COVID-19 Vaccination

Discordant Cellular and Humoral Responses to a 3-Dose COVID-19 mRNA Vaccination Schedule in Patients with Hematologic Malignancies

COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA

Radiotherapy Is an Excellent Bridging Strategy in Large B-Cell Lymphoma Patients Selected for CAR T-Cell Therapy

For Better or for Worse: COVID-19 Vaccination during or Early after (Immuno-) Chemotherapy or Hematopoietic Progenitor Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only